2025
ASO Author Reflections: Preoperative Radiation Boost Reduces Re-Excision Rate and Locoregional Treatment Time in Early-Stage Breast Cancer Patients
Chakraborty M, Haffty B. ASO Author Reflections: Preoperative Radiation Boost Reduces Re-Excision Rate and Locoregional Treatment Time in Early-Stage Breast Cancer Patients. Annals Of Surgical Oncology 2025, 1-2. PMID: 40897941, DOI: 10.1245/s10434-025-18271-z.Peer-Reviewed Original ResearchEarly-stage breast cancer patientsRe-excision ratesBreast cancer patientsRadiation boostRe-ExcisionCancer patientsEarly-stage
2024
2LBA LBA Oral Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL
Wolf D, Yau C, Haan J, Wehkamp D, Witteveen A, Glas A, Campbell M, Nanda R, Chien J, Shatsky R, Isaacs C, Barcura A, Mittempergher L, Kuilman M, Yee D, DeMichele A, Perlmutter J, Pusztai L, Esserman L, van ’t Veer L. 2LBA LBA Oral Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL. European Journal Of Cancer 2024, 200: 113953. DOI: 10.1016/j.ejca.2024.113953.Peer-Reviewed Original ResearchPrediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy
Arcos D, Ng D, Ke Y, Toh Y, Chan A. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy. Supportive Care In Cancer 2024, 32: 76. PMID: 38170327, PMCID: PMC10764400, DOI: 10.1007/s00520-023-08274-5.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancer patientsBreast cancer patientsTreatment of Cancer Quality of Life QuestionnaireCancer Quality of Life QuestionnaireCancer patientsFemale breast cancer patientsQuality of Life QuestionnaireEORTC QLQ-C30European Organisation for ResearchProspective cohort studyQuality of lifeSymptom progressionGI symptomsQLQ-C30Life QuestionnaireSecondary analysisSymptom trajectoriesCohort studyResultsThe analysisInferential statisticsBaseline inflammatory markersAppetite lossInflammatory biomarkersSymptomsBaseline
2022
The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients.
O'Shaughnessy J, Encarnacion C, O'Neal B, Wong J, Siuliukina N, Sanft T, Jankowitz R, Pegram M, Treuner K, Fox J. The Breast Cancer Index Registry Study: Initial analysis of the first 1,000 patients. Journal Of Clinical Oncology 2022, 40: e12513-e12513. DOI: 10.1200/jco.2022.40.16_suppl.e12513.Peer-Reviewed Original ResearchBreast Cancer IndexExtended endocrine therapyLate distant recurrenceBreast cancer patientsRegistry studyEndocrine therapyDistant recurrenceClinicopathological factorsMedication adherenceCancer patientsHigh riskLower riskHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsEarly-stage breast cancer patientsNCCN Clinical Practice GuidelinesLong-term clinical outcomesPositive breast cancer patientsAssociated clinicopathological factorsAdjuvant endocrine therapyNode-negative patientsNode-positive patientsPrognostic risk groupsClinical practice guidelinesRoutine clinical care
2017
THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism
Young N, Thomas E, Snoad B, Sharma J, Mobeen M, DeVries A, Bratasz A, Lustberg M, Jarjour W, Reinbolt R. THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism. Annals Of The Rheumatic Diseases 2017, 76: 222. DOI: 10.1136/annrheumdis-2017-eular.5424.Peer-Reviewed Original ResearchBreast cancer patientsEarly-stage breast cancer patientsAromatase inhibitor-related arthralgiaStage breast cancer patientsBreast cancer researchSerum cytokine levelsBreast cancer survivorsAromatase inhibitorsNovel animal modelInflammatory mechanismsCancer patientsCytokine levelsCancer survivorsMusculoskeletal symptomsRisk factorsHistopathological analysisProspective characterizationAI treatmentHormone receptor-positive breast cancer patientsAnimal modelsReceptor-positive breast cancer patientsNFκB activationAromatase Inhibitor-Induced ArthralgiaBioluminescent imagingKnee jointGait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPatient-reported outcomesTaxane-based chemotherapyCancer patientsChemotherapy cyclesEarly-stage breast cancer patientsPatient-reported symptom severityDevelopment of CIPNSubsequent chemotherapy cyclesFirst chemotherapy cyclePatient-reported symptomsDose-limiting toxicityOutpatient oncology clinicsSelf-reported symptomsTaxane infusionTaxane therapyTaxane treatmentCIPN symptomsDose intensityPeripheral neuropathyOncology clinicPatient functionPhysical functionFunctional deficitsGait testing
2014
Comparison of weight loss among early-stage breast cancer patients post chemotherapy: Nutrition education in combination with weight loss acupuncture versus nutrition education alone.
Fukui J, Rothwell A, Danesh H, Adelson K, Morris G, Irie H, Port E, Weltz C, Schmidt H, Montgomery G, Mandeli J, Tiersten A. Comparison of weight loss among early-stage breast cancer patients post chemotherapy: Nutrition education in combination with weight loss acupuncture versus nutrition education alone. Journal Of Clinical Oncology 2014, 32: tps652-tps652. DOI: 10.1200/jco.2014.32.15_suppl.tps652.Peer-Reviewed Original ResearchEarly-stage breast cancer patientsNutrition educationBreast cancer patientsCancer patientsWeight lossChemotherapyAcupuncturePatients
2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining
2010
Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy
Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG. Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 1236-1243. PMID: 21093162, DOI: 10.1016/j.ijrobp.2010.07.031.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBlack PeopleBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapyTissue Array AnalysisVascular Endothelial Growth Factor AWhite PeopleConceptsEarly-stage breast cancerBreast-Conserving TherapyLocal relapse-free survivalRelapse-free survivalVascular endothelial growth factorEarly-stage breast cancer patientsLocal relapseBreast cancer patientsBreast cancerEndothelial growth factorVEGF expressionOverall survivalPrognostic valueCancer patientsTissue microarrayEstrogen receptor/progesterone receptor statusDistant metastasis-free survivalNodal relapse-free survivalGrowth factorProgesterone receptor statusInstitutional review board approvalMetastasis-free survivalLong-term outcomesMargin-negative patientsOverexpression of VEGFOutcomes following local therapy for early-stage breast cancer in non-trial populations
Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Research And Treatment 2010, 125: 803-813. PMID: 20376555, PMCID: PMC2924956, DOI: 10.1007/s10549-010-0865-4.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryEarly-stage breast cancerClinical trialsBreast cancerEarly-stage breast cancer patientsPrimary breast cancer therapyPrimary breast cancer treatmentEnd Results cancer registryNon-trial populationBreast cancer patientsPopulation-based dataBreast cancer treatmentBreast cancer therapyNon-selected populationPropensity score analysisMedicare administrative dataMore mastectomiesPrimary therapyLocal therapySurveillance EpidemiologyAdjusted survivalCancer RegistryCancer patientsHospital characteristicsMastectomy
2009
Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-stage Breast Cancer Patients Treated with Breast Conservation Therapy
Moran M, Yang Q, Goyal S, Haffty B. Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-stage Breast Cancer Patients Treated with Breast Conservation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s7-s8. DOI: 10.1016/j.ijrobp.2009.07.043.Peer-Reviewed Original ResearchClinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy
Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG. Clinicopathologic Significance of Excision Repair Cross-Complementation 1 Expression in Patients Treated With Breast-Conserving Surgery and Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2009, 76: 679-684. PMID: 19464815, DOI: 10.1016/j.ijrobp.2009.02.050.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalHuman epidermal growth factor receptor 2Cause-specific survivalLower T stageMetastasis-free survivalBreast conservation therapyERCC-1 expressionERCC1 expressionAdjuvant chemotherapyHormonal therapyER positivityOverall survivalT stageConservation therapyProgesterone receptorBreast cancerEstrogen receptorNodal negativityRadiation therapyWorse distant metastasis-free survivalEarly-stage breast cancer patientsLocoregional recurrence-free survivalEarly-stage breast cancerEpidermal growth factor receptor 2Adjuvant hormonal therapy
2008
Prognostic Implications of Mammographically Occult, Early Stage Breast Cancer Patients Treated with Breast Conservation Therapy
Yang T, Yang Q, Haffty B, Moran M. Prognostic Implications of Mammographically Occult, Early Stage Breast Cancer Patients Treated with Breast Conservation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s92. DOI: 10.1016/j.ijrobp.2008.06.976.Peer-Reviewed Original ResearchStandard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907
Muss H, Berry D, Cirrincione C, Theodoulou M, Mauer A, Cohen H, Partridge A, Norton L, Hudis C, Winer E. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. Journal Of Clinical Oncology 2008, 26: 507-507. DOI: 10.1200/jco.2008.26.15_suppl.507.Peer-Reviewed Original ResearchEarly-stage breast cancer patientsBreast cancer patientsStandard chemotherapyCancer patientsCapecitabineChemotherapyPatients
2007
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value In Health 2007, 10: 367-376. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrostadienesAntineoplastic ProtocolsAromatase InhibitorsBreast NeoplasmsCost-Benefit AnalysisDrug Administration ScheduleFemaleForecastingHumansMarkov ChainsMiddle AgedNeoplasm Recurrence, LocalPostmenopauseQuality-Adjusted Life YearsSEER ProgramSelective Estrogen Receptor ModulatorsTamoxifenConceptsIntergroup Exemestane StudyDisease-free survivalDisease-related eventsTreatment strategiesEarly-stage breast cancer patientsEarly-stage breast cancerProlongs disease-free survivalCost-effective treatment strategyIncremental cost-effectiveness ratioYears of tamoxifenYears of therapyBreast cancer patientsSEER-Medicare dataBreast cancer statusLifetime medical care costsMedical care costsCost-effectiveness ratioTamoxifen therapyPostmenopausal womenRecurrence rateCancer careCancer patientsPatient transitionsAromatase inhibitorsBreast cancerSurveillance Testing Among Survivors of Early-Stage Breast Cancer
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Surveillance Testing Among Survivors of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2007, 25: 1074-1081. PMID: 17369571, DOI: 10.1200/jco.2006.08.6876.Peer-Reviewed Original ResearchMeSH KeywordsAgedBreast NeoplasmsCohort StudiesDiagnostic Tests, RoutineFemaleFollow-Up StudiesGuideline AdherenceHumansLogistic ModelsLong-Term CareMedical OncologyNeoplasm StagingOdds RatioOffice VisitsPopulation SurveillancePractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareSEER ProgramSurvivorsTime FactorsUnited StatesUnnecessary ProceduresConceptsBreast cancer survivorsChest X-rayMedical oncologistsCancer survivorsBreast cancerAbdominal imagingAntigen testingBone scanStage I/II breast cancerEarly-stage breast cancer patientsMost breast cancer survivorsEnd Results-Medicare dataSurveillance testingEarly-stage breast cancerRepeated-measures logistic regressionBreast cancer patientsLow-risk populationPopulation-based cohortTypes of physiciansRoutine surveillance testingRate of testingAntigen testCancer patientsWomen's ageSurveillance years
2000
Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation
Turner B, Gumbs A, Carter D, Glazer P, Haffty B. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1169-1176. PMID: 10889369, DOI: 10.1016/s0360-3016(00)00525-3.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast cancer patientsDistant disease-free survivalCancer patientsRadiation therapyOverall survivalEarly-stage breast cancer patientsEarly breast cancer recurrenceAxillary lymph node involvementCycD1 expressionTotal median doseBreast tumor recurrenceDisease-free survivalLymph node involvementBreast cancer populationBreast cancer recurrenceBreast tumor relapseCyclin D1 expressionCyclin D1 levelsMedian doseNode involvementMetastatic diseaseLate relapsePrognostic significancePatient population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply